Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript

SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The reports are tied to Global. The first report grouped here was at 22 Oct 2026, 02:24 UTC. 2 material updates are listed in the timeline. The headline in use is “Cosmo N.V. (CMOPF) Discusses Positive Phase 2 Results and Differentiation of Rifamycin 1% Gel in Ulcerative Colitis and Proctitis Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.